Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare.

• This booster extension is intended to provide both homologous and first heterologous booster data to complement previous positive Phase 1/2 booster results.

• The data are not intended for the initial regulatory approval process, which Valneva expects to finalize in the coming weeks.

• Related: Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows.

• The trial extension will evaluate a booster dose of VLA2001 in adults aged 18 and above who received primary vaccination with two doses of VLA2001.

• The trial will also include participants aged 30 and above who received two doses of AstraZeneca Plc's (NASDAQ: AZN) AZD1222.

• The VLA2001 booster vaccination will be given at least seven months after completing the primary vaccination series.

• Topline data is anticipated in Q2 of 2022.

• Valneva announced the first positive homologous booster results in December 2021.

• In addition, Valneva plans to initiate a further dedicated heterologous booster-only trial of VLA2001 in the coming weeks.

• Valneva expects to complete rolling submissions in the U.K and Bahrain in time and receive potential regulatory approvals in Q1 of 2022.

• Price Action: VALN shares are up 14.0% at $36.08 during the market session on the last check Tuesday.

See more from Benzinga

• Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows

• Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.